GAMIDA CELL LTD. - ORDINARY SHARES

GAMIDA CELL LTD. - ORDINARY SHARES

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Gamida Cell Ltd. - Ordinary Shares_logo
Social Links:

Industry:
Company

Address:
5 Nahum Heftsadie Street, Jerusalem, Israel Zipcode 91340

Country:
Israel

Phone:
972 2 659 5666

Market Cap:
455.25M
Total Assets:
155.48M
Total Cash:
127.17M

Founder: Tony Peled


Key Executives
Name Title Pay Year Born
Dr. Julian Adams Ph.D. CEO & Director 718,000$ 1955(65 years old)
Mr. Shai Lankry CPA, M.B.A. Chief Financial Officer 325,000$ 1976(44 years old)
Dr. Ronit Simantov Chief Medical Officer 560,000$ 1965(55 years old)
Mr. Joshua D. Hamermesh MBA Chief Bus. Officer 494,000$ 1972(48 years old)
Dr. Jas Uppal Chief Regulatory & Quality Officer 487,000$ 1968(52 years old)
Ms. Michele Ilene Korfin M.B.A., R.Ph. Chief Operating & Chief Commercial Officer N/A 1972(48 years old)
Dr. Tracey Lodie Ph.D. Chief Scientific Officer N/A 1970(50 years old)
Mr. Paul Nee VP of Marketing N/A N/A
Mr. Matthew Metivier VP of Human Resource N/A N/A
Mr. Naftali Brikashvili CPA Sr. VP Fin. & Operations N/A N/A



Financial & Stock
Exchange NasdaqGM. Currency in USD. Market state POST
According to Gamida Cell Ltd. - Ordinary Shares's financial reports the company's revenue in 2020 were 0 an decrease(NAN%) over the years 2019 revenue that were of 0. In 2020 the company's total earnings were -72.7M while total earnings in 2019 were -34.35M( +111.76%).
Company's stock symbol is GMDA. Lastest price : 7.69. Total volume :335.40k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.gamida-cell.com

  • Host name: 251.183.232.35.bc.googleusercontent.com
  • IP address: 35.232.183.251
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...
Loading ...


More informations about "Gamida Cell Ltd. - Ordinary Shares" on Search Engine

Gamida Cell Ltd. Ordinary Shares (GMDA) Stock Quotes | Nasdaq

Nasdaq.com Gamida Cell Ltd. Ordinary Shares (GMDA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and

Stocknews.com Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK.

Gamida Cell Ltd. (GMDA) Stock Price, News, Quote & History

Finance.yahoo.com Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference. Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious ...

Gamida Cell Announces Launch of Proposed Public Offering

Investors.gamida-cell.com Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares – Investors – Gamida Cell Ltd.

Gamida Cell Announces Launch of Public Offering of

Investors.gamida-cell.com Gamida Cell Announces Launch of Public Offering of Ordinary Shares – Investors – Gamida Cell Ltd.

Gamida Cell Announces Launch of Public Offering of

Marketwatch.com Dec 16, 2020 · Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the...

Gamida Cell - Cell and Immune Therapy Technologies

Gamida-cell.com Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares Read More. May 18, 2020 ... Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update ... Read More. Feb 21, 2019 Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord ...

Gamida Cell Announces Pricing of $60 Million Public

Investors.gamida-cell.com BOSTON--(BUSINESS WIRE)--May 18, 2020-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before …

Gamida Cell Announces Launch of Proposed Public Offering

Finance.yahoo.com May 19, 2020 · In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold …

Gamida Cell Announces Launch of Proposed Public Offering

Investors.gamida-cell.com Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares – Investors – Gamida Cell Ltd.

GMDA - Gamida Cell Ltd. - Ordinary Shares Summary, Stock

Benzinga.com Jan 01, 2010 · Gamida Cell Ltd. - Ordinary Shares GMDA: ... Gamida Cell shares are trading higher after the company reported the results of the efficacy and …

Gamida Cell Ltd. Ordinary Shares (GMDA) Institutional

Nasdaq.com Find the latest Institutional Holdings data for Gamida Cell Ltd. Ordinary Shares (GMDA) at Nasdaq.com.

Gamida Cell Announces Pricing of $60 Million Public

Finance.yahoo.com In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 2,000,000 ordinary shares at the public offering price, less the underwriting discounts and ...

Gamida Cell Announces Launch of Public Offering of

Morningstar.com Dec 17, 2020 · Gamida Cell Announces Launch of Public Offering of Ordinary Shares Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic...

Gamida Cell Announces Pricing of $65 Million Public

Bloomberg.com Dec 17, 2020 · Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares Business Wire BOSTON -- December 17, 2020 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company ...

Gamida Cell Ltd. Ordinary Shares (GMDA) After-Hours Quotes

Nasdaq.com Gamida Cell Ltd. Ordinary Shares (GMDA) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

Gamida Cell Ltd. Ordinary Shares (GMDA) Press Releases

Nasdaq.com Mar 15, 2021 · Find the latest press releases from Gamida Cell Ltd. Ordinary Shares (GMDA) at Nasdaq.com.

Gamida Cell Ltd. Ordinary Shares (GMDA) Earnings Report

Nasdaq.com Find the latest Earnings Report Date for Gamida Cell Ltd. Ordinary Shares (GMDA) at Nasdaq.com.

SEC Filing – Investors – Gamida Cell Ltd.

Investors.gamida-cell.com Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) February 16, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule …

Gamida Cell Announces Launch of Proposed Public Offering

Businesswire.com May 18, 2020 · In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold …

Gamida Cell Announces Pricing of $65 Million Public

Businesswire.com Dec 17, 2020 · BOSTON-- (BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a...

Gamida Cell Announces Launch of Public Offering of

Biospace.com Dec 17, 2020 · BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares.In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares …

Gamida Cell Announces Pricing of $60 Million Public

Businesswire.com In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 2,000,000 ordinary shares at the public offering price, less the underwriting discounts and ...

Gamida Cell Announces Pricing of $65 Million Public

Globalbankingandfinance.com Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and estimated offering …

SEC.gov | HOME

Sec.gov Gamida Cell Ltd. 5 Nahum Heftsadie St. Givaat Shaul, Jerusalem 91340 Israel +972 (2) 659-5666 . ... Portion of the Ordinary Shares that were automatically added to the shares authorized for issuance under the 2017 Plan on January 1, 2019 and January 1, 2020, pursuant to an “evergreen” provision contained in the 2017 Plan. ...

Gamida Cell Announces Launch of Public Offering of

Apnews.com Dec 17, 2020 · BOSTON--(BUSINESS WIRE)--Dec 16, 2020--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares …

Gamida Cell Announces Pricing of $60 Million Public

Uk.finance.yahoo.com Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and ...

Gamida Cell Announces $75 Million Financing with

Businesswire.com Feb 16, 2021 · Subject to certain limitations, the holders of the notes can elect to exchange the notes for Gamida Cell’s ordinary shares at an initial exchange rate of 56.3063 shares per $1,000 principal ...

Gamida Cell Announces Pricing of $65 Million Public

Biospace.com Dec 17, 2020 · BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd.. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting …

Gamida Cell : Announces Launch of Public Offering of

Marketscreener.com Gamida Cell Ltd. , an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary…

Gamida Cell Announces Pricing of $65 Million Public

Eresearch.fidelity.com BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (GMDA) , an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions …

SEC.gov | HOME

Sec.gov Exhibit 5.1 . Ramat Gan, May 8, 2020 . Gamida Cell Ltd. 5 Nahum Heftsadie Street. Givaat Shaul, Jerusalem 91340. Israel . RE: Registration on Form S-8 Ladies and Gentlemen: We have acted as Israeli counsel to Gamida Cell Ltd., a company organized under the laws of the State of Israel (the “Company”), in connection with its filing of a registration statement on Form S-8 on or about May 8 ...

www.sec.gov

Sec.gov On March 9, 2021, Gamida Cell Ltd. (the “Company”) issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 6-K. The information included under the captions “Omidubicel, an investigational advanced cell therapy for allogeneic bone marrow transplant,” “GDA-201, an innate NK cell immunotherapy,” “Corporate Highlights,” “Full Year 2020 Financial Results ...

GMDA Gamida Cell Ltd. Stock Quote - FINVIZ.com

Finviz.com Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Statement of Ownership (sc 13g)

Ih.advfn.com Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) February 16, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: ¨ Rule 13d-1(b) x: Rule 13d-1(c) ¨ Rule ...

Gamida Cell Announces $75 Million Financing with

Marketwatch.com Feb 16, 2021 · Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic...

Gamida Cell Announces Launch of Proposed Public Offering

Biospace.com May 18, 2020 · BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the launch of a proposed follow-on public offering of its ordinary shares.In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares …

Gamida Cell : Announces Pricing of $60 Million Public

Marketscreener.com Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and ...

Amended Statement of Ownership (sc 13g/a)

Ih.advfn.com GMDA Gamida Cell Ltd Amended Statement of Ownership (sc 13g/a) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1)* ...

SEC.gov | HOME

Sec.gov Gamida Cell Ltd. On February 16, 2021, Gamida Cell Ltd. (the “Company”) issued a press release announcing the closing of an offering of 5.875% exchangeable senior notes due in 2026 (the “Notes”), in the aggregate original principal amount of $75,000,000, a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Issuer on Form 6-K (this “Report”).

Gamida Cell Announces Pricing of $65 Million Public

Uk.finance.yahoo.com Dec 17, 2020 · Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and …

ARK Investment Management LLC reports 72.75% increase in

Fintel.io GMDA / Gamida Cell Ltd. / Elbit Imaging Ltd - SCHEDULE 13G Passive Investment. 2019-02-14 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Gamida Cell Ltd. (Name of Issuer) Ordinary Share, NIS 0.01 par value (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2018 (Date of Event …

Gamida Cell Announces Launch of Proposed Public Offering

Businesswire.com Jun 24, 2019 · In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to $4.5 million of additional ordinary shares at the public offering price, less underwriting discounts ...

SEC.gov | HOME

Sec.gov Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 13,333,334 shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 ...